{"success":true,"data":{"pressRelease":{"id":"7382","rtpr_id":"nGNX1GsB8Z","ticker":"REGN","exchange":"NASDAQ","all_tickers":["REGN"],"title":"Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.","author":"Globe Newswire","published_at":"2026-04-23T19:46:16.134Z","article_body":"Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently\napproved gene therapy for an ultra-rare form of genetic hearing loss, for free\nin the U.S.\n\nRegeneron will lower Medicaid prices based on prices in other developed\ncountries; prices for future medicines in the U.S. will be aligned with prices\nset in that defined group of other countries\n\nPraluent(®) (alirocumab), an important cardiovascular medicine, will be\navailable for direct patient purchase through TrumpRx.gov\n\nRegeneron will continue its large investment in domestic R&D and manufacturing\ncapacity\n\nTARRYTOWN, N.Y., April 23, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,\nInc. (NASDAQ: REGN) today announced an agreement with the U.S. government to\nhelp lower prices of several of its current and future life-changing medicines\nand offer an important new medicine for free in the U.S., ensuring American\npatients gain broader access to innovative treatments.\n\nRegeneron leaders and co-founders Leonard Schleifer, M.D., Ph.D., and George\nYancopoulos, M.D., Ph.D., joined President Donald J. Trump and members of his\nAdministration at the White House to discuss the new agreement, through which\nRegeneron has addressed the four requests set forth in the President’s July\n31(st) letter with existing and new programs.\n\n\"For too long, American patients and taxpayers have shouldered a\ndisproportionate share of the cost of biotechnology innovation — effectively\nsubsidizing lower drug prices for other high-income nations that have not been\npaying their fair share,” said Dr. Schleifer, Board co-Chair, President and\nChief Executive Officer of Regeneron. “Vilifying the biopharma industry has\nnot produced lower prices for Americans, nor has it generated more innovation.\nFor more than a decade, we have argued that the most direct path to meaningful\nrelief for American patients depends on getting other high-income countries to\nfinally contribute their fair share to the cost of the breakthroughs they rely\non just as much as we do. We hope that today’s agreement, coupled with\neffective trade policy, will lead to closer equilibration of prices around the\nglobe while preserving innovation and lowering prices for Americans.”\n\nAs part of the agreement, Regeneron will lower Medicaid prices based on those\nin other developed countries and will align U.S. prices of future medicines\nwith prices set in that defined group of other countries. Regeneron will also\nutilize the TrumpRx.gov platform to allow eligible patients to directly\npurchase Praluent(®) (alirocumab), Regeneron’s PCSK9 inhibitor medicine, at\nthe most-favored nation price.\n\nAdditionally, Regeneron will offer its gene therapy Otarmeni™ (lunsotogene\nparvec-cwha, formerly known as DB-OTO), which was recently approved by the\nU.S. Food and Drug Administration\n(https://www.globenewswire.com/Tracker?data=qcxjlrHdftP4qyhFdbmmIrIz7W42kIDjqlKGfMmoLLGxrtxmJZVlsE4j-rYYSn7W1kkdI8XCSFNx8yyiZYanDjmrohInj5ujYU5d4zPMug2MvElnraMP7fYa8PI82DEcIGf3jUf-B3tQt2yc0q1G1lCx7YD0vLJH5uKa0EWTRA_352tXwzkoe8MaAeaLpyYrXRbbGrUsmKPOY1E2HXJ6asKYlMoMmPfeq5T6ROcWuEOyCUXpt8ze_1hudkVt4oP2xkES0I4xzb2ayBXOfMd8zOYqKN5Tu8HOrIjhXEBl1tw=),\nfor free in the U.S. to treat people with severe to profound and profound\nhearing loss due to variants of the otoferlin gene.\n\n\"Discovering and developing transformative new medicines is among the most\nchallenging endeavors in all of science, and among the most consequential for\naddressing the cost and burden of disease. It demands that we invest deeply in\nthe biotech ecosystem that has the power to push the boundaries of what is\npossible, not just incrementally, but boldly,” said Dr. Yancopoulos, Board\nco-Chair, President and Chief Scientific Officer of Regeneron. “Otarmeni,\nour first-of-its-kind gene therapy for a form of genetic hearing loss, is a\npowerful reminder of what becomes possible when brilliant minds have the\nresources and freedom to pursue difficult challenges. Our decision to provide\nOtarmeni for free in the United States serves to highlight our belief that the\nbiopharmaceutical industry can be a genuine force for good in the world.\"\n\nRegeneron will not be subject to future pricing mandates and will receive\ntariff relief for three years through an agreement with the U.S. Department of\nCommerce under which Regeneron has committed to certain activities and\ninvestments to support R&D and manufacturing in the U.S. Regeneron is one of\nthe largest manufacturers of biologics in the world and has already committed\nover $9 billion of U.S.-based manufacturing and R&D infrastructure investments\nin coming years.\n\nAdditional terms of the agreement remain confidential.\n\nAbout Regeneron \nRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents,\ndevelops and commercializes life-transforming medicines for people with\nserious diseases. Founded and led by physician-scientists, our unique ability\nto repeatedly and consistently translate science into medicine has led to\nnumerous approved treatments and product candidates in development, most of\nwhich were homegrown in our laboratories. Our medicines and pipeline are\ndesigned to help patients with eye diseases, allergic and inflammatory\ndiseases, cancer, cardiovascular and metabolic diseases, neurological\ndiseases, hematologic conditions, infectious diseases, and rare diseases.\n\nRegeneron pushes the boundaries of scientific discovery and accelerates drug\ndevelopment using our proprietary technologies, such as VelociSuite(®), which\nproduces optimized fully human antibodies and new classes of bispecific\nantibodies. We are shaping the next frontier of medicine with data-powered\ninsights from the Regeneron Genetics Center(®) and pioneering genetic\nmedicine platforms, enabling us to identify innovative targets and\ncomplementary approaches to potentially treat or cure diseases. For more\ninformation, please visit www.Regeneron.com or follow Regeneron on LinkedIn\n(https://www.globenewswire.com/Tracker?data=3lfB5CHtjN5ai2z4UMPiVXJbnmprE4xcw5A2akE3_wI24L0WJTMaTh5Tj4lt5JFi5o0HIw3aBM_fk2BwcYO1gWSWVaYrP3yoP2R4hNRokrEhbzZcoZ-2I7JdT1UTk-pE),\nInstagram\n(https://www.globenewswire.com/Tracker?data=HQqgCLDFxfh0ZxpK7PJqFyA21dG0yB3UbU1GwxZRGLRb_c96NvRKXG-5Jt8aiC89tJHgijPJMj4QObbq-oARv-NmXLqk9i7twPhuotTyYWE=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=qapIDKvUlzL1FYjH7KBbEotphW-27UG2WHiuVu8mxHydZTHe4WqIXNdVJQwnooqnqt6BOy8y2djg9mRKFV_DtOIJvXqrAUoxp-Y42q8TcAI=)\nor X\n(https://www.globenewswire.com/Tracker?data=CLCaj-8FsJCAp60uS2zSW7tKMzXbBcpYwRqtNas2GucdEk6-8FtIyfToGIzvPOxD8A4jSv_pw6FoaeyfsMcf9g==).\n\nForward-Looking Statements and Use of Digital Media\nThis press release includes forward-looking statements that involve risks and\nuncertainties relating to future events and the future performance of\nRegeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and\nactual events or results may differ materially from these forward-looking\nstatements. Words such as “anticipate,” “expect,” “intend,”\n“plan,” “believe,” “seek,” “estimate,” variations of such\nwords, and similar expressions are intended to identify such forward-looking\nstatements, although not all forward-looking statements contain these\nidentifying words. These statements concern, and these risks and uncertainties\ninclude, among others, changes to drug pricing regulations and requirements\nand Regeneron’s pricing strategy, including the changes pursuant to\nRegeneron’s agreement with the U.S. government discussed in this press\nrelease; other changes in laws, regulations, and policies affecting the\nhealthcare industry; the ability of Regeneron to manage supply chains for\nmultiple products and product candidates and risks associated with tariffs and\nother trade restrictions; the nature, timing, and possible success and\ntherapeutic applications of products marketed or otherwise commercialized by\nRegeneron and/or its collaborators or licensees (collectively,\n“Regeneron’s Products”) and product candidates being developed by\nRegeneron and/or its collaborators or licensees (collectively,\n“Regeneron’s Product Candidates”) and research and clinical programs now\nunderway or planned, including without limitation Praluent(®) (alirocumab)\nand Otarmeni™ (lunsotogene parvec-cwha); uncertainty of the utilization,\nmarket acceptance, and/or commercial success of Regeneron’s Products (such\nas Praluent and Otarmeni) and Regeneron’s Product Candidates and the impact\nof studies (whether conducted by Regeneron or others and whether mandated or\nvoluntary) on any of the foregoing; the likelihood, timing, and scope of\npossible regulatory approval and commercial launch of Regeneron’s Product\nCandidates and new indications for Regeneron’s Products; the ability of\nRegeneron’s collaborators, licensees, suppliers, or other third parties (as\napplicable) to perform manufacturing, filling, finishing, packaging, labeling,\ndistribution, and other steps related to Regeneron’s Products and\nRegeneron’s Product Candidates; safety issues resulting from the\nadministration of Regeneron’s Products (such as Praluent and Otarmeni) and\nRegeneron’s Product Candidates in patients, including serious complications\nor side effects in connection with the use of Regeneron’s Products and\nRegeneron’s Product Candidates in clinical trials; determinations by\nregulatory and administrative governmental authorities which may delay or\nrestrict Regeneron’s ability to continue to develop or commercialize\nRegeneron’s Products and Regeneron’s Product Candidates; ongoing\nregulatory obligations and oversight impacting Regeneron’s Products,\nresearch and clinical programs, and business, including those relating to\npatient privacy; the availability and extent of reimbursement or copay\nassistance for Regeneron’s Products from third-party payors and other third\nparties, including private payor healthcare and insurance programs, health\nmaintenance organizations, pharmacy benefit management companies, and\ngovernment programs such as Medicare and Medicaid; coverage and reimbursement\ndeterminations by such payors and other third parties and new policies and\nprocedures adopted by such payors and other third parties; competing products\nand product candidates (including biosimilar products) that may be superior\nto, or more cost effective than, Regeneron’s Products and Regeneron’s\nProduct Candidates; the extent to which the results from the research and\ndevelopment programs conducted by Regeneron and/or its collaborators or\nlicensees may be replicated in other studies and/or lead to advancement of\nproduct candidates to clinical trials, therapeutic applications, or regulatory\napproval; unanticipated expenses; the costs of developing, producing, and\nselling products; the ability of Regeneron to meet any of its financial\nprojections or guidance and changes to the assumptions underlying those\nprojections or guidance; the potential for any license, collaboration, or\nsupply agreement, including Regeneron’s agreements with Sanofi and Bayer (or\ntheir respective affiliated companies, as applicable), to be cancelled or\nterminated; the impact of public health outbreaks, epidemics, or pandemics on\nRegeneron's business; and risks associated with litigation and other\nproceedings and government investigations relating to the Company and/or its\noperations (including the pending civil proceedings initiated or joined by the\nU.S. Department of Justice and the U.S. Attorney's Office for the District of\nMassachusetts), risks associated with intellectual property of other parties\nand pending or future litigation relating thereto (including without\nlimitation the patent litigation and other related proceedings relating to\nEYLEA(®) (aflibercept) Injection), the ultimate outcome of any such\nproceedings and investigations, and the impact any of the foregoing may have\non Regeneron’s business, prospects, operating results, and financial\ncondition. A more complete description of these and other material risks can\nbe found in Regeneron’s filings with the U.S. Securities and Exchange\nCommission, including its Form 10-K for the year ended December 31, 2025. Any\nforward-looking statements are made based on management’s current beliefs\nand judgment, and the reader is cautioned not to rely on any forward-looking\nstatements made by Regeneron. Regeneron does not undertake any obligation to\nupdate (publicly or otherwise) any forward-looking statement, including\nwithout limitation any financial projection or guidance, whether as a result\nof new information, future events, or otherwise.\n\nRegeneron uses its media and investor relations website and social media\noutlets to publish important information about the Company, including\ninformation that may be deemed material to investors. Financial and other\ninformation about Regeneron is routinely posted and is accessible on\nRegeneron's media and investor relations website\n(https://investor.regeneron.com) and its LinkedIn page\n(https://www.linkedin.com/company/regeneron-pharmaceuticals).\n\nContacts:\n\nMedia Relations \nmedia@regeneron.com\n\nInvestor Relations\nir@regeneron.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/add5ebc7-88c9-49dc-8834-abbb07c622d1)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1GsB8Z","title":"Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.","author":"Globe Newswire","ticker":"REGN","created":"2026-04-23T19:46:16.134Z","tickers":["REGN"],"exchange":"NASDAQ","article_body":"Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently\napproved gene therapy for an ultra-rare form of genetic hearing loss, for free\nin the U.S.\n\nRegeneron will lower Medicaid prices based on prices in other developed\ncountries; prices for future medicines in the U.S. will be aligned with prices\nset in that defined group of other countries\n\nPraluent(®) (alirocumab), an important cardiovascular medicine, will be\navailable for direct patient purchase through TrumpRx.gov\n\nRegeneron will continue its large investment in domestic R&D and manufacturing\ncapacity\n\nTARRYTOWN, N.Y., April 23, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,\nInc. (NASDAQ: REGN) today announced an agreement with the U.S. government to\nhelp lower prices of several of its current and future life-changing medicines\nand offer an important new medicine for free in the U.S., ensuring American\npatients gain broader access to innovative treatments.\n\nRegeneron leaders and co-founders Leonard Schleifer, M.D., Ph.D., and George\nYancopoulos, M.D., Ph.D., joined President Donald J. Trump and members of his\nAdministration at the White House to discuss the new agreement, through which\nRegeneron has addressed the four requests set forth in the President’s July\n31(st) letter with existing and new programs.\n\n\"For too long, American patients and taxpayers have shouldered a\ndisproportionate share of the cost of biotechnology innovation — effectively\nsubsidizing lower drug prices for other high-income nations that have not been\npaying their fair share,” said Dr. Schleifer, Board co-Chair, President and\nChief Executive Officer of Regeneron. “Vilifying the biopharma industry has\nnot produced lower prices for Americans, nor has it generated more innovation.\nFor more than a decade, we have argued that the most direct path to meaningful\nrelief for American patients depends on getting other high-income countries to\nfinally contribute their fair share to the cost of the breakthroughs they rely\non just as much as we do. We hope that today’s agreement, coupled with\neffective trade policy, will lead to closer equilibration of prices around the\nglobe while preserving innovation and lowering prices for Americans.”\n\nAs part of the agreement, Regeneron will lower Medicaid prices based on those\nin other developed countries and will align U.S. prices of future medicines\nwith prices set in that defined group of other countries. Regeneron will also\nutilize the TrumpRx.gov platform to allow eligible patients to directly\npurchase Praluent(®) (alirocumab), Regeneron’s PCSK9 inhibitor medicine, at\nthe most-favored nation price.\n\nAdditionally, Regeneron will offer its gene therapy Otarmeni™ (lunsotogene\nparvec-cwha, formerly known as DB-OTO), which was recently approved by the\nU.S. Food and Drug Administration\n(https://www.globenewswire.com/Tracker?data=qcxjlrHdftP4qyhFdbmmIrIz7W42kIDjqlKGfMmoLLGxrtxmJZVlsE4j-rYYSn7W1kkdI8XCSFNx8yyiZYanDjmrohInj5ujYU5d4zPMug2MvElnraMP7fYa8PI82DEcIGf3jUf-B3tQt2yc0q1G1lCx7YD0vLJH5uKa0EWTRA_352tXwzkoe8MaAeaLpyYrXRbbGrUsmKPOY1E2HXJ6asKYlMoMmPfeq5T6ROcWuEOyCUXpt8ze_1hudkVt4oP2xkES0I4xzb2ayBXOfMd8zOYqKN5Tu8HOrIjhXEBl1tw=),\nfor free in the U.S. to treat people with severe to profound and profound\nhearing loss due to variants of the otoferlin gene.\n\n\"Discovering and developing transformative new medicines is among the most\nchallenging endeavors in all of science, and among the most consequential for\naddressing the cost and burden of disease. It demands that we invest deeply in\nthe biotech ecosystem that has the power to push the boundaries of what is\npossible, not just incrementally, but boldly,” said Dr. Yancopoulos, Board\nco-Chair, President and Chief Scientific Officer of Regeneron. “Otarmeni,\nour first-of-its-kind gene therapy for a form of genetic hearing loss, is a\npowerful reminder of what becomes possible when brilliant minds have the\nresources and freedom to pursue difficult challenges. Our decision to provide\nOtarmeni for free in the United States serves to highlight our belief that the\nbiopharmaceutical industry can be a genuine force for good in the world.\"\n\nRegeneron will not be subject to future pricing mandates and will receive\ntariff relief for three years through an agreement with the U.S. Department of\nCommerce under which Regeneron has committed to certain activities and\ninvestments to support R&D and manufacturing in the U.S. Regeneron is one of\nthe largest manufacturers of biologics in the world and has already committed\nover $9 billion of U.S.-based manufacturing and R&D infrastructure investments\nin coming years.\n\nAdditional terms of the agreement remain confidential.\n\nAbout Regeneron \nRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents,\ndevelops and commercializes life-transforming medicines for people with\nserious diseases. Founded and led by physician-scientists, our unique ability\nto repeatedly and consistently translate science into medicine has led to\nnumerous approved treatments and product candidates in development, most of\nwhich were homegrown in our laboratories. Our medicines and pipeline are\ndesigned to help patients with eye diseases, allergic and inflammatory\ndiseases, cancer, cardiovascular and metabolic diseases, neurological\ndiseases, hematologic conditions, infectious diseases, and rare diseases.\n\nRegeneron pushes the boundaries of scientific discovery and accelerates drug\ndevelopment using our proprietary technologies, such as VelociSuite(®), which\nproduces optimized fully human antibodies and new classes of bispecific\nantibodies. We are shaping the next frontier of medicine with data-powered\ninsights from the Regeneron Genetics Center(®) and pioneering genetic\nmedicine platforms, enabling us to identify innovative targets and\ncomplementary approaches to potentially treat or cure diseases. For more\ninformation, please visit www.Regeneron.com or follow Regeneron on LinkedIn\n(https://www.globenewswire.com/Tracker?data=3lfB5CHtjN5ai2z4UMPiVXJbnmprE4xcw5A2akE3_wI24L0WJTMaTh5Tj4lt5JFi5o0HIw3aBM_fk2BwcYO1gWSWVaYrP3yoP2R4hNRokrEhbzZcoZ-2I7JdT1UTk-pE),\nInstagram\n(https://www.globenewswire.com/Tracker?data=HQqgCLDFxfh0ZxpK7PJqFyA21dG0yB3UbU1GwxZRGLRb_c96NvRKXG-5Jt8aiC89tJHgijPJMj4QObbq-oARv-NmXLqk9i7twPhuotTyYWE=),\nFacebook\n(https://www.globenewswire.com/Tracker?data=qapIDKvUlzL1FYjH7KBbEotphW-27UG2WHiuVu8mxHydZTHe4WqIXNdVJQwnooqnqt6BOy8y2djg9mRKFV_DtOIJvXqrAUoxp-Y42q8TcAI=)\nor X\n(https://www.globenewswire.com/Tracker?data=CLCaj-8FsJCAp60uS2zSW7tKMzXbBcpYwRqtNas2GucdEk6-8FtIyfToGIzvPOxD8A4jSv_pw6FoaeyfsMcf9g==).\n\nForward-Looking Statements and Use of Digital Media\nThis press release includes forward-looking statements that involve risks and\nuncertainties relating to future events and the future performance of\nRegeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and\nactual events or results may differ materially from these forward-looking\nstatements. Words such as “anticipate,” “expect,” “intend,”\n“plan,” “believe,” “seek,” “estimate,” variations of such\nwords, and similar expressions are intended to identify such forward-looking\nstatements, although not all forward-looking statements contain these\nidentifying words. These statements concern, and these risks and uncertainties\ninclude, among others, changes to drug pricing regulations and requirements\nand Regeneron’s pricing strategy, including the changes pursuant to\nRegeneron’s agreement with the U.S. government discussed in this press\nrelease; other changes in laws, regulations, and policies affecting the\nhealthcare industry; the ability of Regeneron to manage supply chains for\nmultiple products and product candidates and risks associated with tariffs and\nother trade restrictions; the nature, timing, and possible success and\ntherapeutic applications of products marketed or otherwise commercialized by\nRegeneron and/or its collaborators or licensees (collectively,\n“Regeneron’s Products”) and product candidates being developed by\nRegeneron and/or its collaborators or licensees (collectively,\n“Regeneron’s Product Candidates”) and research and clinical programs now\nunderway or planned, including without limitation Praluent(®) (alirocumab)\nand Otarmeni™ (lunsotogene parvec-cwha); uncertainty of the utilization,\nmarket acceptance, and/or commercial success of Regeneron’s Products (such\nas Praluent and Otarmeni) and Regeneron’s Product Candidates and the impact\nof studies (whether conducted by Regeneron or others and whether mandated or\nvoluntary) on any of the foregoing; the likelihood, timing, and scope of\npossible regulatory approval and commercial launch of Regeneron’s Product\nCandidates and new indications for Regeneron’s Products; the ability of\nRegeneron’s collaborators, licensees, suppliers, or other third parties (as\napplicable) to perform manufacturing, filling, finishing, packaging, labeling,\ndistribution, and other steps related to Regeneron’s Products and\nRegeneron’s Product Candidates; safety issues resulting from the\nadministration of Regeneron’s Products (such as Praluent and Otarmeni) and\nRegeneron’s Product Candidates in patients, including serious complications\nor side effects in connection with the use of Regeneron’s Products and\nRegeneron’s Product Candidates in clinical trials; determinations by\nregulatory and administrative governmental authorities which may delay or\nrestrict Regeneron’s ability to continue to develop or commercialize\nRegeneron’s Products and Regeneron’s Product Candidates; ongoing\nregulatory obligations and oversight impacting Regeneron’s Products,\nresearch and clinical programs, and business, including those relating to\npatient privacy; the availability and extent of reimbursement or copay\nassistance for Regeneron’s Products from third-party payors and other third\nparties, including private payor healthcare and insurance programs, health\nmaintenance organizations, pharmacy benefit management companies, and\ngovernment programs such as Medicare and Medicaid; coverage and reimbursement\ndeterminations by such payors and other third parties and new policies and\nprocedures adopted by such payors and other third parties; competing products\nand product candidates (including biosimilar products) that may be superior\nto, or more cost effective than, Regeneron’s Products and Regeneron’s\nProduct Candidates; the extent to which the results from the research and\ndevelopment programs conducted by Regeneron and/or its collaborators or\nlicensees may be replicated in other studies and/or lead to advancement of\nproduct candidates to clinical trials, therapeutic applications, or regulatory\napproval; unanticipated expenses; the costs of developing, producing, and\nselling products; the ability of Regeneron to meet any of its financial\nprojections or guidance and changes to the assumptions underlying those\nprojections or guidance; the potential for any license, collaboration, or\nsupply agreement, including Regeneron’s agreements with Sanofi and Bayer (or\ntheir respective affiliated companies, as applicable), to be cancelled or\nterminated; the impact of public health outbreaks, epidemics, or pandemics on\nRegeneron's business; and risks associated with litigation and other\nproceedings and government investigations relating to the Company and/or its\noperations (including the pending civil proceedings initiated or joined by the\nU.S. Department of Justice and the U.S. Attorney's Office for the District of\nMassachusetts), risks associated with intellectual property of other parties\nand pending or future litigation relating thereto (including without\nlimitation the patent litigation and other related proceedings relating to\nEYLEA(®) (aflibercept) Injection), the ultimate outcome of any such\nproceedings and investigations, and the impact any of the foregoing may have\non Regeneron’s business, prospects, operating results, and financial\ncondition. A more complete description of these and other material risks can\nbe found in Regeneron’s filings with the U.S. Securities and Exchange\nCommission, including its Form 10-K for the year ended December 31, 2025. Any\nforward-looking statements are made based on management’s current beliefs\nand judgment, and the reader is cautioned not to rely on any forward-looking\nstatements made by Regeneron. Regeneron does not undertake any obligation to\nupdate (publicly or otherwise) any forward-looking statement, including\nwithout limitation any financial projection or guidance, whether as a result\nof new information, future events, or otherwise.\n\nRegeneron uses its media and investor relations website and social media\noutlets to publish important information about the Company, including\ninformation that may be deemed material to investors. Financial and other\ninformation about Regeneron is routinely posted and is accessible on\nRegeneron's media and investor relations website\n(https://investor.regeneron.com) and its LinkedIn page\n(https://www.linkedin.com/company/regeneron-pharmaceuticals).\n\nContacts:\n\nMedia Relations \nmedia@regeneron.com\n\nInvestor Relations\nir@regeneron.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/add5ebc7-88c9-49dc-8834-abbb07c622d1)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-23T19:46:16.176494626Z","server_sent_at_ms":1776973576176},"received_at":"2026-04-23T19:46:16.229Z","source_url":null},"analysis":{"id":"5554","press_release_id":"7382","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"regulatory","narrative":"Regeneron reached a major agreement with the U.S. government to lower Medicaid prices and align future U.S. drug costs with other developed nations.\n\nIn exchange, the company receives three years of tariff relief and exemption from future pricing mandates, while committing over $9 billion to domestic manufacturing and R&D.\n\nThe company will provide its newly approved gene therapy Otarmeni for free in the U.S. and make Praluent available for direct purchase via TrumpRx.gov.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Regeneron secures pricing exemptions and tariff relief in a landmark deal with the U.S. government."},"keyFigures":{"customDimensions":{"committed_rd_investment_usd":"over $9 billion","tariff_relief_duration_years":3}},"quotedText":"For more than a decade, we have argued that the most direct path to meaningful relief for American patients depends on getting other high-income countries to finally contribute their fair share to the cost of the breakthroughs they rely on just as much as we do.","namedEntities":{"people":[{"name":"Leonard Schleifer","role":"Board co-Chair, President and Chief Executive Officer"},{"name":"George Yancopoulos","role":"Board co-Chair, President and Chief Scientific Officer"},{"name":"Donald J. Trump","role":"President"}],"products":["Otarmeni (lunsotogene parvec-cwha)","Praluent (alirocumab)","VelociSuite"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN"},{"name":"U.S. Department of Commerce","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"over $9 billion","context":"U.S.-based manufacturing and R&D infrastructure investments"}]},"materialImpact":{"score":5,"reasoning":"The company secured a landmark agreement with the U.S. government providing tariff relief and exemption from future pricing mandates. This protects future pricing power and margins while addressing political pressure. Additionally, the provision of Otarmeni for free and the commercialization via TrumpRx.gov for Praluent represent significant strategic shifts in access."},"tickerRelevance":{"others":[],"primary":"REGN"},"eventTypeSecondary":["product_launch"]},"event_type":"regulatory","event_type_secondary":["product_launch"],"sentiment":"bullish","material_impact_score":5,"narrative":"Regeneron reached a major agreement with the U.S. government to lower Medicaid prices and align future U.S. drug costs with other developed nations.\n\nIn exchange, the company receives three years of tariff relief and exemption from future pricing mandates, while committing over $9 billion to domestic manufacturing and R&D.\n\nThe company will provide its newly approved gene therapy Otarmeni for free in the U.S. and make Praluent available for direct purchase via TrumpRx.gov.","key_figures":{"customDimensions":{"committed_rd_investment_usd":"over $9 billion","tariff_relief_duration_years":3}},"named_entities":{"people":[{"name":"Leonard Schleifer","role":"Board co-Chair, President and Chief Executive Officer"},{"name":"George Yancopoulos","role":"Board co-Chair, President and Chief Scientific Officer"},{"name":"Donald J. Trump","role":"President"}],"products":["Otarmeni (lunsotogene parvec-cwha)","Praluent (alirocumab)","VelociSuite"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN"},{"name":"U.S. Department of Commerce","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"over $9 billion","context":"U.S.-based manufacturing and R&D infrastructure investments"}]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-23T23:28:49.301Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:55.119Z"}},"durationMs":25080,"modelName":"glm-4.7"}}